Multiple Myeloma Treatment
Clinical research centers on newly diagnosed multiple myeloma, relapsed or refractory multiple myeloma, and high-risk smoldering multiple myeloma, with interest in both transplant-eligible and transplant-ineligible populations. Studies also address extramedullary disease and younger patients eligible for autologous stem cell transplantation.
- Induction therapy
- Consolidation treatment
- Maintenance therapy
- Transplant-related treatment strategies
Research activity includes combinations built around daratumumab, isatuximab, teclistamab, talquetamab, elranatamab, and ciltacabtagene autoleucel.
AL Amyloidosis
The sponsor funds studies in immunoglobulin light-chain (AL) amyloidosis, including both previously treated and relapsed or refractory disease. This area includes evaluation of therapies for organ-involved plasma cell disorders linked to amyloid light-chain production.
- Hematologic response
- Relapsed disease management
- Novel antibody-based therapies
Active research includes agents such as teclistamab and belantamab mafodotin in the amyloidosis setting.
Minimal Residual Disease and Response Monitoring
A major research focus is minimal residual disease (MRD) assessment in multiple myeloma, including comparisons of next-generation sequencing and other blood- or marrow-based monitoring approaches. Trials examine MRD status across post-consolidation, maintenance, and post-transplant settings.
- MRD negativity
- Complete response
- Progression-free survival
- Response depth assessment
Research also includes biomarker-linked monitoring in newly diagnosed disease and treatment-adapted follow-up after combination therapy.
Transplant and Post-Transplant Strategies
Trials investigate treatment pathways around autologous stem cell transplantation in newly diagnosed multiple myeloma, with attention to both induction and post-transplant consolidation. The sponsor also supports studies in transplant-ineligible patients and in younger patients receiving transplant-oriented care.
- Pre-transplant induction
- Post-transplant consolidation
- Maintenance approaches
- Transplant-eligible patient care
Research commonly involves proteasome inhibitors, immunomodulatory agents, and CD38-targeted therapies in combination regimens.
Relapse Prevention and Combination Regimens
Additional studies focus on treatment combinations for previously untreated and previously treated multiple myeloma, including regimens designed to improve disease control after initial therapy or during maintenance. These programs include interest in trispecific antibodies, bispecific antibodies, and novel oral agents.
- Relapsed or refractory multiple myeloma
- Maintenance combinations
- Novel immunotherapy
- Response improvement
Therapeutic areas include selinexor, pomalidomide, elotuzumab, iberdomide, and lenalidomide-based strategies.
